Quantitative structure-activity relationship studies of cyclooxygenase inhibitors: A comprehensive analysis

Drug Development Research

Volumn 64, Issue 4, 2005, Pages 220-231

  Prasanna, S ^a,b   Manivannan, E ^a   Chaturvedi, S C ^a  

^a DEVI AHILYA UNIVERSITY   (India)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

ClogP; CMR; COX 1; COX 2; QSAR

Indexed keywords

ALKENE DERIVATIVE; AROMATIC COMPOUND; ARYLPROPIONIC ACID DERIVATIVE; BENZENE DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FLURBIPROFEN; GW 406381; IBUPROFEN; LIGAND; NIMESULIDE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONAMIDE;

ARTICLE; DRUG BINDING SITE; DRUG SELECTIVITY; ENZYME INHIBITION; HYDROPHOBICITY; MODEL; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY;

EID: 23244462984     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10432     Document Type: Article

References (32)

1. Bekhit AA, Abdel-Aziem T. 2004. Design, synthesis and biological evaluation of some pyrazole derivatives as anti-inflammatory-antimicrobial agents. Bioorg Med Chem 12:1935-1945.
2. Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S, Wiseman J. 2004. Identification of 2,3-diaryl-pyrazolo[1, 5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 14:5445-5448.
3. Black WC. 2004. Selective cyclooxygenase-2 Inhibitors. Ann Rep Med Chem 39:125-138.
4. Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Reindeau D, Silva J, Styhler A, Trimble LA, Nicoll-Griffth DA. 2001. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 11:1059-1062.
5. FitzGerald GA, Patrono C. 2001. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433-442.
6. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, Ackerman NR. 1990. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254:180-187.
7. Garg R, Kurup A, Mekapati SB, Hansch C. 2003. Cyclooxygenase (COX) inhibitors: a comparative QSAR study. Chem Rev 103:703-732.
8. Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ. 2004. Manipulation of kinetic profiles in 2-aryl propionic acid Cyclooxygenase inhibitors. Bioorg Med Chem Lett 14:667-671.
9. Hansch C. 1981. The physicochemical approach to drug design and discovery (QSAR). Drug Dev Res 1:267-309.
10. Hansch C, Leo A. 1979. Substitution constants for correlation analysis in chemistry and biology. New York: John Wiley & Sons.
11. Hansch C, Leo A. 1995. Exploring QSAR: Fundamentals and applications in chemistry and biology. Washington, DC: ACS.
12. Mansch C, Leo A, Hoekman D. 1995. Exploring QSAR: Hydrophobic, electronic and steric constants. Washington, DC: ACS.
13. Hawkey, CJ. 1999. COX-2 inhibitors. Lancet 353:307-314.
14. Julemont F, Levai Xde, Michaux C, Renard J-F, Winum J-Y, Montera J-L, Damas J, Dogne J-M, Pirotte B. 2004. Design, synthesis and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem 47:6749-6759.
15. Manivannan E, Prasanna S, Chaturvedi SC. 2004. Rationalization of physico-chemical properties of 5, 6-diarylthiazolo [3,2-b]-1, 2, 4-triazoles towards cyclooxygenase-2 (COX-2) inhibition: A QSAR approach. Indian J Biochem Biophys 41:184-187.
16. Pal M, Veeramaneni VR, Nagabelli M, Kalleda SR, Misra P, Casturi SR, Yelewarapu KR. 2003. Conformationally restricted 3, 4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 13:1639-1643.
17. Penning TD, Talley JJ, Bertenshaw, SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. 1997. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 40:1347-1635.
18. Picot D, Loll PJ, Garavito RM. 1994. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367:243-249.
19. Pommery N, Taverne T, Telliez A, Gossens L, Charlier C, Pommery J, Goossens J-F, Houssin R, Durant F, Henichart J-P. 2004. New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J Med Chem 47:6195-6206.
20. Prasanna S, Manivannan E, Chaturvedi SC. 2004a. Quantitative structure-activity relationship analysis of a series of 2,3-diaryl benzopyran analogues as novel selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 14:4005-4011.
21. Prasanna S, Manivannan E, Chaturvedi SC. 2004b. QSAR analysis of 2,3-diaryl benzopyrans/pyrans as selective COX-2 inhibitors based on semiempirical AMI calculations. QSAR and Comb Sci 23:621-628.
22. Prasanna S, Manivannan E, Chaturvedi SC. 2004c. QSAR analysis of some fused pyrazoles as selective cyclooxygenase-2 inhibitors: a Hansch approach. Arch Pharm Pharm Med Chem 337:440-444.
23. Prasanna S, Manivannan E, Chaturvedi SC. 2004d. QSAR analysis of 2,2-dimethyl-4,5-diarylfuran-3(2H)-ones as selective cyclooxygenase-2 inhibitors. Ind J Chem 438:2249-2253.
24. Prasanna S, Manivannan E, Chaturvedi SC. 2005a. QSAR studies on structurally similar 2-(4-methanesulfonylphenyl)pyran-4-ones as selective COX-2 inhibitors: A Hansch approach. Bioorg Med Chem Lett 15:313-320.
25. Prasanna S, Manivannan E, Chaturvedi SC. 2005b. QSAR analyses of conformationally restricted 1,5diaryl pyrazoles as selective COX-2 inhibitors: application of connection table representation of ligands. Bioorg Med Chem Lett 15:2097-2102.
26. Prasit P, Wang Z, Brideau, C, Chan C-C, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gorden R, Guay J, Gresser M, Kargman S, Kennedy B, Leflanc Y, Leger S, Mancini J, O'Neil GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Tagari P, Therien M, Vickers P, Wang E, Xu L-J, Young RN, Zambani R, Boyce S, Rupniak N, Forest M, Visco D, Patrick D. 1999. The discovery of rofecoxib [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett 9:1773-1778.
27. Reddy MVR, Mallireddigari MR, Pallele VR, Venkatapuram P, Boominathan R, Bell SC, Reddy EP. 2005. Design, synthesis and biological evaluation of (E) and (Z)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors. Bioorg Med Chem 13:1715-1723.
28. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K. 2000. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 43:775-777.
29. Uddin MdJ, Rao PNP, Knaus EE. 2005a. Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-lenes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2-(COX-2) with anti-inflammatory and analgesic activity. Bioorg Med Chem Lett 13:417-424.
30. Uddin MdJ, Rao PNP, McDonald R, Knaus EE. 2005b. Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. Bioorg Med Chem Lett 15:439-442.
31. Ulbrich H, Fiebich B, Dannhardt G. 2002. Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6,7-diaryl-2,3-1H- dihydropyrrolizine type. Eur J Med Chem 37:953-959.
32. Verloop A, Hoogenstraaten W, Tipker J. 1976. In Drug Design, vol. 7. Ariens, E. J., Ed., New York: Academic Press. 165.